If Your Baby’s Eczema Keeps Coming Back, It’s Probably Not The Cream’s Fault — It’s What The Cream Can’t Reach
By Sarah Holloway, Consumer Health Writer · Last Updated: September 23, 2026
If you have spent the last several months cycling through every emollient, barrier cream, and gentle moisturiser recommended for infant eczema — and your baby’s skin is still flaring — you are not doing anything wrong. The more likely explanation is that the products themselves are designed to work on the surface of the skin, and the biological problem driving your baby’s eczema begins somewhere the cream was never formulated to reach. A growing body of research into the way infant skin actually builds and maintains its own protective barrier has clarified something that standard product formulations have not yet caught up with: for a significant proportion of children with eczema, the skin is not simply dry. It is structurally incomplete at a cellular level — and no amount of topical moisture applied from the outside will rebuild what needs to be rebuilt from within.
1. Most infant eczema products treat the symptom you can see, not the structure that broke down underneath it
When a baby’s skin flares, the visible problem — redness, dryness, broken skin, persistent itch — is real and urgent. But it is a symptom of a deeper structural failure, and the way we typically respond to symptoms is to address them where we can see them: on the surface. Emollients and barrier creams occupy this space. They are formulated to temporarily reduce water loss through the outermost skin layer, and within that limited scope, they work. The skin looks and feels more hydrated while the product is present. The difficulty is that they are functioning as a temporary patch on a wall that is structurally unsound — and as soon as the patch wears off, the wall fails again in exactly the same place.
The structural component that is failing in eczema-prone skin is a protein called filaggrin. Filaggrin is produced within the skin’s own cells and is responsible for binding the corneocytes — the outermost skin cells — together into a tightly sealed barrier. In healthy skin, this barrier prevents water from escaping and keeps environmental irritants and microbes from entering. In skin with eczema, filaggrin production is reduced or disrupted, and the barrier behaves more like a loosely woven fabric than a sealed membrane. Moisture escapes freely. Irritants enter. Immune cells detect the breach and generate an inflammatory response. What you observe as a flare is the downstream consequence of that structural failure — not the cause of it.
Applying a topical moisturiser to this skin is not wrong. But it addresses the consequence without touching the cause. The filaggrin deficit remains. The barrier remains structurally incomplete. And the next flare follows the same pathway as every flare before it.
2. The skin's own repair process depends on a specific amino acid — and most infants with eczema aren't getting enough of it
Filaggrin is a protein, and like all proteins, it is built from amino acids. The amino acid that functions as the primary precursor to filaggrin is L-histidine. The skin cannot synthesise L-histidine on its own — it is classed as an essential amino acid, meaning it must be supplied from external sources, either through diet or supplementation. In adults and older children, a reasonably varied diet often provides enough. In infants — particularly those on restricted diets due to food allergy concerns, which are disproportionately common in children with eczema — the supply is frequently inadequate.
This creates a situation where the skin is attempting to repair its own barrier from a position of material shortage. It is not a failure of the skin’s repair mechanism; it is a failure of supply to that mechanism. The biological machinery for filaggrin synthesis exists. The blueprint is present. But without sufficient L-histidine available, the production line cannot run at full capacity, and the barrier remains thinner and more porous than it needs to be.
Published research has established a relationship between L-histidine availability and filaggrin expression in the skin. This is not a fringe or speculative connection — it is a mechanistic pathway that explains, at least in part, why eczema skin consistently underproduces the protein responsible for barrier integrity. It also explains why topical treatment alone, however well-formulated, is structurally limited in its ability to fully resolve the condition: the raw material the skin needs to repair itself is not something a cream can deliver. It is something that must be supplied from within.
3. Standard baby soaps and cleansers often strip the very protection they're supposed to preserve
Cleansing is a necessary part of caring for eczema-prone infant skin. Bathing removes environmental allergens, reduces microbial load on the skin surface, and is a moment of relief during an active flare. But the cleansing step is also one of the most common unintentional sources of ongoing barrier damage in infants with eczema — and most parents are not aware of it, because the products causing the damage are labelled as gentle and designed for babies.
The problem is surfactant chemistry. Surfactants — the agents that allow soap to lift dirt and oil from the skin — do not discriminate between the debris they are meant to remove and the natural lipids that belong in the skin barrier. The ceramides, fatty acids, and oils that form a critical component of the barrier matrix are partially solubilised and rinsed away during washing. In skin with healthy filaggrin production, this loss is tolerable because the barrier regenerates efficiently between washes. In eczema-prone skin, where the barrier is already structurally compromised and regenerating slowly, repeated stripping during cleansing accelerates the breakdown faster than the skin can recover.
Fragrance and preservative ingredients in many conventional baby washes compound the problem by triggering low-grade inflammatory responses in sensitised skin, even when the concentration is well below what would cause a visible reaction in unaffected skin. The cumulative effect is that the twice-daily bath intended to soothe the baby is, in part, extending the very cycle it is meant to interrupt. A cleansing formula for eczema-prone infant skin must be able to remove genuine impurities without compromising the lipid layer the skin is trying to maintain — and must be free of ingredients that trigger the sensitised immune responses that drive eczema inflammation in the first place.
4. Treating eczema from the outside only addresses half the biology driving it
There is a well-established connection between the health of the gut microbiome and the behaviour of the immune system at the skin surface — a relationship researchers refer to as the gut-skin axis. In simplified terms: the gut microbiome plays a significant role in calibrating immune responses across the body, including the type of inflammatory response that drives eczema. When the balance of gut microbiota is disrupted — a state called dysbiosis — the immune system can become dysregulated in ways that manifest as heightened skin sensitivity and more frequent or severe inflammatory flares.
In infants, the gut microbiome is in an early and relatively unstable phase of development. It is more easily disrupted by factors including antibiotic exposure, mode of delivery at birth, feeding method, and early dietary introduction than in older children or adults. This makes the gut-skin connection particularly relevant for infant eczema — and particularly underaddressed by the standard topical-only treatment model, which has no mechanism for influencing what is happening downstream in the immune and microbiome system.
A topical lotion applied twice daily cannot modulate gut microbiome composition. A gentle soap cannot reduce systemic immune dysregulation. These are legitimate and necessary tools for managing the skin surface, but they are tools designed for half the problem. The inside component of the biology — the gut-immune-skin axis — requires a different approach entirely, one that is administered internally and sustained long enough to produce measurable changes in microbiome balance and immune calibration. In the context of infant eczema, that means looking at the full picture of what is happening in the body, not only what is visible on the skin.
5. Without a structured protocol, even the right individual products tend to underperform
One of the most consistent patterns in how families manage infant eczema is fragmentation. A gentle soap here, a specialist lotion there, occasional steroid cream during severe flares, perhaps a probiotic at the suggestion of a health visitor, then discontinuation when the routine becomes too complex to sustain. Each of these choices may be individually defensible. But eczema biology is not addressed in fragments — it is addressed by a coordinated, sustained approach that targets the barrier, the microbiome, and the external environment simultaneously over a sufficient time period to produce structural change.
A 30-day sustained protocol changes something that a two-week trial of a single product cannot. The skin barrier does not fully regenerate overnight. Gut microbiome composition does not shift in response to a few doses of a probiotic. The amino acid availability needed for filaggrin synthesis needs to be consistently maintained, not spiked and withdrawn. When any one of these components is present without the others, or is used inconsistently or for too short a window, the results are partial and impermanent — which is exactly the experience most eczema parents describe when they reflect on what they have already tried.
The fragmented approach is not a failure of parental diligence. It is a natural consequence of a market that has, until recently, offered only individual products without a coherent system for using them together. What a genuine protocol provides is not simply a bundle of products — it is a sequence, a structure, and a time frame that allows each component to do its work in coordination with the others.
So What Can You Actually Do About It?
The core problem is this: infant eczema driven by a compromised skin barrier cannot be fully resolved by any approach that only addresses the surface, because the barrier’s structural deficit originates inside the skin’s own cells — and is maintained, in part, by biological conditions in the gut and immune system that topical products were never designed to reach.
A protocol genuinely capable of addressing this needs to meet the following criteria:
- ✓ Supply the specific amino acid — L-histidine — that the skin needs to produce filaggrin and rebuild its barrier at a cellular level
- ✓ Support the cleanest possible skin surface environment through a cleanser that removes impurities without stripping the skin’s own protective lipid layer or disrupting the microbiome
- ✓ Deliver targeted topical hydration and barrier-supporting actives to the skin surface in parallel with the internal repair process
- ✓ Be formulated and validated as safe for infant skin from as young as three months — not adapted from an adult formulation
- ✓ Run as a complete, coordinated 30-day protocol so each component can do its work in the right sequence, over a sufficient time window, for results that last
This Is What A Complete Inside-Out Protocol For Infant Eczema Actually Looks Like
For parents who have worked through the science above and recognise the gap it describes, Codex Labs has built a three-step system — the Eczema Relief Skin Barrier Protocol (Infant) — specifically to address infant eczema at each of the three levels where the biology breaks down: the internal supply of barrier-building nutrients, the microbiome-safe cleansing environment, and the topical restoration of the skin surface itself.
The protocol is formulated for infants from three months of age. Every component is corticosteroid-free. And it is designed as a coordinated 30-day system — not a collection of standalone products, but a sequenced protocol in which each step supports the work of the others.
L-Histidine supplement sachets formulated for infants feed the specific amino acid the skin needs to produce filaggrin, supporting barrier reconstruction at the cellular level — not just at the surface.
BIA Eczema Relief Lotion with filaggrin-promoting actives delivers deep hydration and targeted barrier-restoration topically, working in parallel with the internal supplement to support skin repair from both directions simultaneously.
Unscented glycerin soap bar free from fragrances, dyes, and harsh surfactants cleanses without stripping the skin’s natural lipid layer or disrupting the microbiome, so the cleansing step supports the barrier instead of undermining it.
How The Three-Step Protocol Works
Step 1 — Internal: Supply the building blocks
Each day, one sachet of the infant supplement is mixed into milk, formula, or soft food. The sachets deliver L-histidine alongside zinc and antioxidant co-factors — the nutritional inputs the skin needs to sustain filaggrin synthesis over the 30-day protocol window. This is the step that no topical product can replicate. It works internally, providing the raw material for structural barrier repair rather than compensating for the barrier’s absence at the surface. Parents who have used only topical treatments previously will notice that nothing about this step looks like conventional eczema care — because it isn’t. It is the component that makes everything applied to the surface subsequently more likely to hold.
Step 2 — Cleanse: Protect what you’re trying to build
At bath time, the unscented glycerin soap bar cleanses the skin without the surfactant chemistry that strips lipids or the fragrance chemistry that triggers sensitised immune responses. This matters because every cleansing cycle is an opportunity either to support the barrier repair work happening from within or to partially undo it. A soap that strips natural lipids creates a recovery deficit the skin must spend time and resources repairing before it can make any net progress on barrier reconstruction. The glycerin formula is designed to clean without that cost — so the barrier-building work done internally is not eroded away at the sink.
Step 3 — Topical: Reinforce the barrier from the outside
After bathing and throughout the day as needed, the BIA Eczema Relief Lotion delivers hydration and filaggrin-promoting actives directly to the skin surface. Applied to skin that has been cleansed without being stripped, and that is receiving consistent internal nutritional support, the lotion is working with the grain of what the skin is already attempting to do — not against a deficit it cannot close on its own. The result is a coordinated inside-out approach: internal supply meets external reinforcement, in a sequence that gives each step the conditions it needs to perform.
What To Expect Over 30 Days
First days: The cleansing step typically produces the most immediately perceptible change. Parents often notice that skin does not feel tight or reactive after bathing when a microbiome-safe, fragrance-free formula is used in place of a conventional baby wash. The lotion absorbs cleanly and does not require the heavy re-application cycle that can develop when the cleansing step is stripping moisture faster than topical products can replace it.
First two weeks: The supplement sachets are working to support filaggrin synthesis during this period. Barrier protein production is not a process that produces visible results overnight — the skin’s cell turnover cycle means that structural changes at the cellular level take time to manifest at the surface. What this period is building is the biological foundation that the later weeks of the protocol depend on. Some parents notice a reduction in the frequency of minor irritation events during this period; others do not observe visible change until the third or fourth week.
By 30 days: The 30-day window is the point at which all three components of the protocol have had sufficient time to work in coordination. The internal L-histidine supply has been consistently available for filaggrin synthesis across multiple skin cell turnover cycles. The cleansing routine has protected the barrier from repeated stripping events. The topical lotion has provided continuous surface-level hydration and barrier support. Parents following the complete protocol consistently are in the position the system is designed to create: a skin barrier that has had the conditions, the nutritional raw materials, and the external reinforcement it needs to begin functioning more like healthy skin.
The Protocol Is Backed By A Satisfaction Guarantee
Codex Labs stands behind the protocol with a satisfaction guarantee. If you follow the complete three-step system for the full protocol period and do not feel it has supported your baby’s skin in the way the science describes, contact the Codex Labs team directly for a resolution.
This exists because the company is aware that parents arriving at this protocol have typically spent months — and often considerably more money — on approaches that did not deliver lasting results. The guarantee is structured to remove the risk of that experience repeating. You follow the protocol as designed. You assess the outcome honestly. If it has not worked for you, the purchase is protected.
The Eczema Relief Skin Barrier Protocol (Infant) — Complete 3-Step System
Save $3.50 when you purchase the protocol as a bundle: $67.50 versus $71.00 purchased separately
This is the complete system as described above: the L-histidine supplement sachets to support filaggrin production from within, the BIA Eczema Relief Lotion to restore and hydrate the barrier at the surface, and the unscented glycerin soap bar to protect the barrier through every cleansing cycle. All three components are formulated for infant skin from three months of age, corticosteroid-free, and designed to work as a coordinated 30-day protocol — not as standalone products that happen to be packaged together.
Bundled pricing is available as part of the current promotion. Pricing subject to change.
Secure checkout · Free of corticosteroids · Formulated for infants from 3 months
Privacy Policy · Terms of Service · Returns & Refunds · Contact Us
This article is produced in partnership with Codex Labs Corp and contains sponsored content. The information presented on this page is intended for educational purposes only and does not constitute medical advice. The Eczema Relief Skin Barrier Protocol (Infant) is not intended to diagnose, treat, cure, or prevent any disease or medical condition. Individual results vary. Parents of infants with eczema or other skin conditions should consult a qualified healthcare provider before introducing new supplements or skincare products, particularly for children under twelve months of age. Claims referencing clinical validation, filaggrin support, or skin barrier function reflect the brand’s product formulation rationale; independent peer-reviewed clinical trial data specific to this product should be requested from Codex Labs directly before making a purchase decision.
Advertising disclosure: This page is a sponsored advertorial. The author or publisher may receive compensation in connection with purchases made through links on this page. Results from the use of any supplement or skincare protocol depend on individual health status, protocol adherence, and other factors outside the brand’s or publisher’s control.